These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3025916)

  • 1. Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies.
    Glennon RA; Titeler M; Young R
    Psychopharmacol Bull; 1986; 22(3):953-8. PubMed ID: 3025916
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of drug discrimination procedures to characterize hallucinogenic drug actions.
    Appel JB; Cunningham KA
    Psychopharmacol Bull; 1986; 22(3):959-67. PubMed ID: 3797596
    [No Abstract]   [Full Text] [Related]  

  • 3. Hallucinogens as discriminative stimuli.
    Winter JC
    Fed Proc; 1974 Jul; 33(7):1825-32. PubMed ID: 4209212
    [No Abstract]   [Full Text] [Related]  

  • 4. Screening hallucinogenic drugs II. Systematic study of two behavioral tests.
    Calil HM
    Psychopharmacology (Berl); 1978 Jan; 56(1):87-92. PubMed ID: 415331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus properties of hallucinogens and related designer drugs.
    Glennon RA
    NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of operant behavior by hallucinogenic drugs.
    Rech RH; Mokler DJ
    Psychopharmacol Bull; 1986; 22(3):968-72. PubMed ID: 3797597
    [No Abstract]   [Full Text] [Related]  

  • 7. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
    Marona-Lewicka D; Nichols DE
    Pharmacol Biochem Behav; 2007 Oct; 87(4):453-61. PubMed ID: 17618679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EEG and behavioral effects in animals of some amphetamine derivatives with hallucinogenic properties.
    Florio V; Fuentes JA; Ziegler H; Longo VG
    Behav Biol; 1972 Jun; 7(3):401-14. PubMed ID: 5067663
    [No Abstract]   [Full Text] [Related]  

  • 9. Some effects of hallucinogenic morning-glory seeds on the behavior of rats.
    Gutherz K; Sperling SE
    Psychol Rep; 1966 Dec; 19(3):949-50. PubMed ID: 5981107
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioral pharmacology of PCP, NMDA and sigma receptors.
    Balster RL
    NIDA Res Monogr; 1989; 95():270-4. PubMed ID: 2561831
    [No Abstract]   [Full Text] [Related]  

  • 11. [A method of long-term local action on the neuromediator system of nuclei of the brain].
    Iakimovskiĭ AF
    Fiziol Zh SSSR Im I M Sechenova; 1988 Mar; 74(3):439-42. PubMed ID: 2838342
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of changes in adrenergic and cholinergic activity upon acquisition of operant discrimination in albino rats.
    Houser VP
    Psychol Rep; 1973 Jun; 32(3):1311-27. PubMed ID: 4709829
    [No Abstract]   [Full Text] [Related]  

  • 13. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP) on successive sensory discrimination behavior maintained by electrical stimulation of the brain reinforcement in the rat.
    Vincent JH; Lenzer II
    Psychol Rep; 1976 Jun; 38(3 Pt 2):1083-92. PubMed ID: 935303
    [No Abstract]   [Full Text] [Related]  

  • 15. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of continuous treatment with increasing doses of medazepam on a program of light discrimination].
    Provenzano PM; Gianguzza S; Coppola A
    Arch Sci Biol (Bologna); 1973; 57(1-2):57-63. PubMed ID: 4154734
    [No Abstract]   [Full Text] [Related]  

  • 17. C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
    McLean TH; Chambers JJ; Parrish JC; Braden MR; Marona-Lewicka D; Kurrasch-Orbaugh D; Nichols DE
    J Med Chem; 2006 Jul; 49(14):4269-74. PubMed ID: 16821786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic actions of clonidine.
    Lal H; Shearman GT
    Prog Clin Biol Res; 1981; 71():99-145. PubMed ID: 6276904
    [No Abstract]   [Full Text] [Related]  

  • 20. A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA.
    Young R; Glennon RA
    J Pharmacol Exp Ther; 1996 Feb; 276(2):594-601. PubMed ID: 8632326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.